Bavarian will use own money to start RSV trials, but is still seeking a partner
After several discussions with the FDA, Bavarian Nordic has finally finished designing the study of its RSV vaccine and will start a 12,000 person phase III study in 2021.
As the end of the year approaches, Bavarian Nordic has started to look towards 2020, and has revealed two central points of next year's work: the purchase of two new vaccines from Glaxosmithkline and a timeline for the company's large phase III test of a vaccine against airway virus RSV.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
